- MediWound (NASDAQ:MDWD) completes the enrollment of 175 subjects in its Phase 3 DETECT study assessing NexoBrid in severe burn and wound management. Topline results should be available by year-end.
- The primary endpoint is the proportion of patients experiencing complete eschar removal compared to gel vehicle (placebo) or standard of care. Long-terms effects will be assessed at months 12 and 24.
- Results from a recent Europe-based Phase 3 showed a 96.3% rate of eschar removal with NexoBrid.
MediWound completes enrollment in late-stage study of NexoBrid
Recommended For You
More Trending News
About MDWD Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MDWD | - | - |
MediWound Ltd. |